MétaCan
Menu
Back to cohort
Record W1986388359 · doi:10.1517/14656560802653206

Economic evaluation of docetaxel for breast cancer

2009· review· en· W1986388359 on OpenAlexaff
Zarnie Lwin, Natasha B. Leighl

Bibliographic record

VenueExpert Opinion on Pharmacotherapy · 2009
Typereview
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsPrincess Margaret Cancer CentreUniversity of Toronto
Fundersnot available
KeywordsDocetaxelMedicineTaxaneBreast cancerOncologyCancerInternal medicineProstate cancerAdjuvantChemotherapyIntensive care medicine

Abstract

fetched live from OpenAlex

Zarnie Lwin MBBS FCP(SA) FRACPa & Natasha Leighl MD MMSc FRCPC*aa University of Toronto, Princess Margaret Hospital, Division of Medical Oncology and Haematology, 5-105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada, USA +1 416 946 4645; +1 416 946 6546; † Author for correspondenceBreast cancer is among the leading causes of cancer morbidity worldwide and accounts for a significant proportion of overall healthcare costs. Cost-effectiveness and cost-utility evaluations of therapy provide insight into the societal value of different treatments, helping decision-makers to prioritize resource allocation and maximize benefit in cancer control within resource constraints. Docetaxel, a plant alkaloid of the taxane group, has been recognized as a highly active chemotherapy agent in breast, lung and prostate cancers, among others. In the last decade, docetaxel has become incorporated into the neoadjuvant, adjuvant and metastatic treatment of breast cancer. This article reviews the economic data supporting the use of docetaxel in the treatment of breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.005
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.197
GPT teacher head0.554
Teacher spread0.357 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueExpert Opinion on PharmacotherapySame topicCancer Treatment and PharmacologyFrench-language works237,207